# Patent Watch: Metrc Claims Data-Driven Cannabis

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/patent-watch-patent-watch-metrc-claims-data-driven-cannabi-2026-10-10/
> **Published:** 2026-10-10T22:50:24-04:00 | **Last Modified / Clinically Audited:** 2026-10-10T22:50:24-04:00
> **Clinical Summary:** US20260094116A1 describes a system for establishing industry norms and recording regulated cannabis across cultivation, production, harvest, and packaging.

---

PATENT WATCH
 US20260094116A1
 
 

# Patent Watch: Metrc Claims Data-Driven Cannabis Regulation System

 
 **Assignee:** Metrc LLC
 **Inventors:** DILEK DAGDELEN UYSAL, JEFFREY LANE WELLS
 **Published:** 2026-04-02
 
 

 
 Invention Summary & Claims
 

US20260094116A1 describes a system for establishing industry norms and recording regulated cannabis across cultivation, production, harvest, and packaging. Its disclosed embodiment treats recorded products as legal and unrecorded products as illegal, although actual legal status depends on applicable law and compliance requirements. The invention concerns regulatory data infrastructure, not active pharmaceutical ingredients, excipients, drug delivery mechanisms, or clinical indications.

 

 

## Clinical Perspective & Therapeutic Significance

 

Reliable product tracking could support traceability, recall management, and investigation of supply-chain irregularities, potentially benefiting patients and providers. However, a recorded product is not necessarily free of contaminants, accurately labeled, or therapeutically appropriate. The disclosure establishes no improvement in cannabinoid bioavailability, dosing precision, or treatment outcomes.

 

## Intellectual Property & Market Landscape

 

Metrc LLC operates in cannabis regulatory compliance and seed-to-sale tracking, positioning this application within oversight infrastructure rather than therapeutic product development. Unlike patents covering cannabinoid formulations or delivery devices, this IP addresses how products are documented and monitored. Its commercial significance depends on claim scope, adoption, and differentiation from existing tracking systems.

 
 **Official Source Document:** Review the primary patent disclosure and full claims on [Google Patents (US20260094116A1)](https://patents.google.com/patent/US20260094116A1/en).
 

 
 Editorial Commentary
 

This application is more consequential for cannabis accountability than for treatment innovation. For patients and clinicians, traceability can complement laboratory testing and clinical assessment, but cannot replace either.

 

 
 

### Frequently Asked Questions

 
 Does a cannabis product recorded in this system become safer or medically approved?
 No. Recording supports regulatory oversight, but does not itself establish product purity, accurate potency, medical approval, or suitability for a particular patient.

 Does this patent application demonstrate successful clinical trials?
 No. A published patent application describes intellectual property claims, not proof of clinical efficacy, and the disclosed system is regulatory infrastructure rather than a treatment.

 When could patients access a treatment based on this application?
 The application does not identify a new treatment or therapeutic launch timeline. Patients could benefit indirectly if the claimed tracking approach is implemented, but publication alone does not establish deployment.

 

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 
 Physician-Led, Whole-Person Care
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.
 
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Cannabis Consultation](https://cedclinic.com/book/)
 
 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).